We welcome Dr. Axel Petzold as new member in the IMSVISUAL Board of Directors. Dr. Petzold graduated from the Medical University of Freiburg (Germany). He received his MD in Experimental Ophthalmology with Ted Sharpe (University of Freiburg) and his PhD in Biochemistry with Ed Thompson (University College London). He trained as a neurologist in France (Lyon), Germany (Munich) and the United Kingdom (London). He currently works as consultant neurologist at Moorfields Eye Hospital London UK, the UCL Institute of Neurology and the VU Medical Center Amsterdam. In his research he focusses on axonal degeneration mainly in multiple sclerosis and optic nerve disease but also other diseases and models.
Dr. Petzold follows Dr. Villoslada, who now works at Genentech as Senior Medical Director, Late Clinical Development Neurosciences. We wish Dr. Villoslada all the best at Genentech and thank him for his tremendous effort to found IMSVISUAL.
We also welcome Dr. Lisanne Balk as new member of the IMSVISUAL Working Committee. Dr. Balk is a clinical epidemiologist, currently working as a post-doctoral researcher at the MS Centre, VU Medical Centre Amsterdam. Her research is focused on the use of optical coherence tomography in MS.
Dear IMSVISUAL Members, Dear Colleagues,
It is our pleasure to invite you to our next IMSVISUAL Consortium meeting at ECTRIMS in Paris on Friday, October 27, from 5 to 8 p.m. Please see details on the meeting venue in the attached PDF. A meeting agenda will be circulated in the next few weeks. Please indicate your attendance by email to Maria Weinhold (firstname.lastname@example.org).
We encourage all IMSVISUAL members (in particular our younger colleagues) to briefly present ideas for future collaborative research projects within IMSVISUAL as well as recent own research. If you are interested in presenting your work, or would like to share ideas for future projects we suggest that you state this in your registration email and provide a short tentative title.
We are looking forward to seeing you in Paris.
PDF flyer for IMSVISUAL Paris 2017
Thank you all for attending the IMSVISUAL meeting at ACTRIMS 2017! Here are the slide decks:
IMSVISUAL members from Berlin and Munich in Germany have just published the following paper:
Oertel & Kuchling et al. Neurol Neuroimmunol Neuroinflamm May 2017 vol. 4 no. 3 e334
Objective: To trace microstructural changes in patients with aquaporin-4 antibody (AQP4-ab)-seropositive neuromyelitis optica spectrum disorders (NMOSDs) by investigating the afferent visual system in patients without clinically overt visual symptoms or visual pathway lesions.
Methods: Of 51 screened patients with NMOSD from a longitudinal observational cohort study, we compared 6 AQP4-ab–seropositive NMOSD patients with longitudinally extensive transverse myelitis (LETM) but no history of optic neuritis (ON) or other bout (NMOSD-LETM) to 19 AQP4-ab–seropositive NMOSD patients with previous ON (NMOSD-ON) and 26 healthy controls (HCs). Foveal thickness (FT), peripapillary retinal nerve fiber layer (pRNFL) thickness, and ganglion cell and inner plexiform layer (GCIPL) thickness were measured with optical coherence tomography (OCT). Microstructural changes in the optic radiation (OR) were investigated using diffusion tensor imaging (DTI). Visual function was determined by high-contrast visual acuity (VA). OCT results were confirmed in a second independent cohort.
Results: FT was reduced in both patients with NMOSD-LETM (p = 3.52e−14) and NMOSD-ON (p = 1.24e−16) in comparison with HC. Probabilistic tractography showed fractional anisotropy reduction in the OR in patients with NMOSD-LETM (p = 0.046) and NMOSD-ON (p = 1.50e−5) compared with HC. Only patients with NMOSD-ON but not NMOSD-LETM showed neuroaxonal damage in the form of pRNFL and GCIPL thinning. VA was normal in patients with NMOSD-LETM and was not associated with OCT or DTI parameters.
Conclusions: Patients with AQP4-ab–seropositive NMOSD without a history of ON have microstructural changes in the afferent visual system. The localization of retinal changes around the Müller-cell rich fovea supports a retinal astrocytopathy.
Available as Open Access on the publisher’s website.
On Friday, February 24, 2017 the ACTRIMS Forum 2017 hosts the
SS3. International MS Visual System Consortium (IMSVISUAL) Symposium
from 4:30 pm–5:45 pm.
Check out the details on the official ACTRIMS website.
Looking forward to seeing you in Orlando!
In this retrospective study, which was just published in Neurology, Julia Button and colleagues investigate differences in retinal atrophy progression dependent on disease-modifying treatment.
EUPON inspires European multidisciplinary collaborations to further the knowledge in ophthalmological and neurological optic nerve pathologies.
The 2nd conference will take place in Barcelona, Spain from March 17th to 18th 2017.
The exciting programs covers important diseases like MS, NMO, LHON, PD and AD!
See you in Barcelona!
Scientists from Berlin have developed an intravital multiphoton microscopy prototype for repeated retinal measurements in mice. Using this system, Bremer et al. investigated neuronal dysfunction in the retinal ganglion cell layer in an experimental autoimmune uveoretinitis model.
The results of the study have been published in Frontiers in Immunology on Dec 23rd 2016 and are available in full as open access.
Pache & Zimmermann et al. just published a study investigating afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. MOG-antibodies have recently been identified in a subgroup of patients with neuromyelitis optica and in patients with recurrent optic neuritis.
The paper has been published in Journal of Neuroinflammation 2016 13:282.
The study is part of a series of 4 papers describing different aspects of MOG-IgG in NMO and related disorders.
Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
Part 3: Brainstem involvement – frequency, presentation and outcome
Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients